Previous 10 | Next 10 |
The iShares Nasdaq Biotechnology ETF includes both COVID-19 and other plays. The ETF is up by 26% during the last year and there are questions around further growth. While some analysts have a neutral stance, there are some indications which point to more upside, despite uncertain...
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at the 39th Annual J.P. Mo...
-- VUI-202012/01 Variant May Increase SARS-CoV-2 Transmissibility by 70% -- -- Controls to be Used to Develop, Verify and Validate Tests that Identify More Transmissible Variant -- Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed t...
Twist Bioscience (TWST) seeks to expand its manufacturing and commercial capabilities with the addition of the "Factory of the Future" just outside of Portland, Oregon in Wilsonville.The facility is expected to become operational in 2022."We are expanding our customer base and ...
-- State-of-the-Art Site Near Portland, Oregon Expected to More than Double Manufacturing Capacity, Increase Speed of Production and Enable Enhanced Product Offerings -- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of ...
Twist Bioscience ([[TWST]] +5.1%) has launched Clonal-Ready Gene Fragments, with and without adapters, can be used to build constructs and minimize the time and cost of screening for perfect clones.The Fragments begin as oligonucleotides synthesized on Twist Bioscience’s semiconductor-...
-- Complete Gene Offering Improved Efficiency for Customers -- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of Clonal-Ready Gene Frag...
Shares of Twist Bioscience are up over 520% in 2020 supported by accelerating demand for synthetic DNA and next-generation-sequencing. Launch of several new products including expanding relationships with key biopharma customers are likely to drive growth going forward. While we r...
ARKG aims to capitalize on a $9Tn TAM with the convergence of AI, DNA Sequencing and Gene-Editing. ARKG is up 149% YTD vs. the SPX return of 13%. Led by Cathie Wood, I think ARKG will be the best performing ARK Fund over the next 10 years. For further details see: ARKG: ...
Twist Bioscience (TWST) has priced its public offering of ~2.8M common shares at $110.00/share, which consists of ~2.73M shares to be sold by Twist and 75K by certain selling stockholders.The gross proceeds are expected to be ~$300M (from $250M).Underwriters' over-allotment is an additional 4...
News, Short Squeeze, Breakout and More Instantly...
Twist Bioscience Corporation Company Name:
TWST Stock Symbol:
NASDAQ Market:
Twist Bioscience Corporation Website:
Pure Biologics’ exploratory Phase 0 study to evaluate pharmacodynamic activity of PBA-0405 in solid tumors Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today a...
Company to host conference call at 8:00 AM ET Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2024 th...
Express Genes enable faster turnaround times Twist Express Antibodies, CHO starting at 13 business days Twist Express Antibodies, HEK293 starting at 10 business days Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of ...